From Symptomatic Relief to Tissue Repair

Targeting both the cause and consequence of inflammatory arthritis

A Revolutionary Approach to Rheumatoid Arthritis

Current RA treatments focus primarily on symptom management through immune suppression, leaving joint damage to progress despite reduced inflammation. MEV-N01 represents a fundamentally different approach: a regenerative EV therapy that simultaneously addresses inflammation while actively promoting tissue repair.

Our lead program demonstrates FT-01's therapeutic potential in a large, well-characterised disease with significant unmet medical need. With millions of RA patients worldwide experiencing inadequate response to current treatments, MEV-N01 offers the possibility of not just managing disease but restoring joint function.

Dual-Action Mechanism

Microscopic image of neurons with red and green fluorescent labels indicating different structures or activities in the cells.

Comprehensive Therapeutic Approach

MEV-N01's unique value lies in its ability to target multiple aspects of RA pathology through a single treatment, leveraging the natural therapeutic properties of FT-01-derived EVs.

  • MEV-N01 contains bioactive factors that modulate inflammatory cascades responsible for joint destruction in RA:

    • Suppression of pro-inflammatory cytokine production

    • Promotion of anti-inflammatory mediator release

    • Regulation of immune cell activation and migration

    • Restoration of immune homeostasis in the joint environment

    • Beyond inflammation control, MEV-N01 actively stimulates repair mechanisms:

      • Enhancement of chondrocyte function and matrix production

      • Promotion of synovial tissue healing

      • Stimulation of endogenous repair pathways

      • Protection of existing cartilage and bone structures

Clinical Development and Evidence

Close-up of a plant or leaf under green fluorescent or glow-in-the-dark light.

Validated Efficacy in Disease Models

MEV-N01 has demonstrated compelling therapeutic effects in rigorous preclinical studies using established RA models. These studies validate both the anti-inflammatory and pro-regenerative properties of FT-01-derived EVs.

    • Significant reduction in joint inflammation and swelling

    • Meaningful improvement in cartilage integrity and bone preservation

    • Dose-dependent efficacy with weekly and twice-weekly administration

    • Sustained therapeutic effects following treatment completion

    • No adverse inflammatory responses

    • Excellent local and systemic tolerability

    • No evidence of immunogenicity or tumorigenic potential

    • Compatible with existing RA treatment regimens

Delivery and Patient Benefits

A healthcare worker wearing blue gloves holding a syringe and a small glass vial, preparing to administer a vaccine or injection.

Minimally Invasive Treatment Approach

MEV-N01 is designed for intra-articular injection directly into affected joints, offering several advantages over systemic therapies:

    • Direct application to the disease site maximises therapeutic concentration

    • Reduced systemic exposure minimises potential side effects

    • Precise dosing enables optimal therapeutic outcomes

    • Compatible with outpatient administration

    • Office-based procedure requiring minimal intervention

    • Potential to delay or prevent joint replacement surgery

    • Preservation of joint function and mobility

    • Improved quality of life through pain reduction and functional improvement

Development Timeline and Future Potential

A scientist in a laboratory handling a test tube rack with multiple orange-tipped pipettes while using a pipette controller device.

Advancing Toward Clinical Translation

MEV-N01's development pathway reflects our commitment to bringing this innovative therapy to patients while advancing FT-01 platform validation

  • Our development approach aligns with regulatory guidance for advanced therapy medicinal products:

    • IND-enabling studies planned for completion by late 2026

    • Clinical trial design informed by preclinical dose-response data

    • Regulatory engagement to optimise development pathway

    • Quality systems established for clinical-grade production

    • Expansion into related inflammatory joint conditions

    • Application to other autoimmune diseases

    • Platform validation for strategic partnerships

    • Foundation for next-generation EV therapeutics

    • Expansion into related inflammatory joint conditions

    • Application to other autoimmune diseases

    • Platform validation for strategic partnerships

    • Foundation for next-generation EV therapeutics

Learn More About
Our Science

Learn more